CoChat
Sign Up
Cited by 1,763Computational Drug Discovery MethodsAnimal testing and alternativesStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.

Why 90% of clinical drug development fails and how to improve it?

Open access
Sun, Duxin, Gao, Wei, Hu, Hongxiang, Zhou, Simon·2022·Acta Pharmaceutica Sinica B
DOI 10.1016/j.apsb.2022.02.002PMC PMC9293739
Open this paper in CoChat — free accountOpen PDF

Abstract

Ninety percent of clinical drug development fails despite implementation of many successful strategies, which raised the question whether certain aspects in target validation and drug optimization are overlooked? Current drug optimization overly emphasizes potency/specificity using structure‒activity-relationship (SAR) but overlooks tissue exposure/selectivity in disease/normal tissues using structure‒tissue exposure/selectivity-relationship (STR), which may mislead the drug candidate selection and impact the balance of clinical dose/efficacy/toxicity. We propose structure‒tissue exposure/selectivity-activity relationship (STAR) to improve drug optimization, which classifies drug candidates based on drug's potency/selectivity, tissue exposure/selectivity, and required dose for balancing clinical efficacy/toxicity. Class I drugs have high specificity/potency and high tissue exposure/selectivity, which needs low dose to achieve superior clinical efficacy/safety with high success rate. Class II drugs have high specificity/potency and low tissue exposure/selectivity, which requires high dose to achieve clinical efficacy with high toxicity and needs to be cautiously evaluated. Class III drugs have relatively low (adequate) specificity/potency but high tissue exposure/selectivity, which requires low dose to achieve clinical efficacy with manageable toxicity but are often overlooked. Class IV drugs have low specificity/potency and low tissue exposure/selectivity, which achieves inadequate efficacy/safety, and should be terminated early. STAR may improve drug optimization and clinical studies for the success of clinical drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2022.02.002

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 106 references

1 of the 106 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Kerns, 2008, Chapter 2—advantages of good drug-like properties, 6
  2. Kerns, 2008, Chapter 19 - pharmacokinetics, 228
  3. Wei Gao, 2022, Structure‒tissue exposure/selectivity relationship (STR) may correlate with clinical efficacy/safety, Acta Pharm Sin B

Cited by

Sorted by citations

Items 301–400 of 1,000

Related

See all

Metadata

Authors
Sun, D., Gao, W., Hu, H., & Zhou, S.
Affiliations
  • University of Michigan (US)
  • Bristol-Myers Squibb (United States) (US)
Corresponding author
Sun, Duxin
ORCID
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2022-07
Volume
12
Issue
7
Pages
3049-3062
ISSN
2211-3835 (ISSN-L)
DOI
10.1016/j.apsb.2022.02.002
PMC
PMC9293739
OpenAlex
W4211238337
Cited by
1,763
References
106
Citations by year
2026: 482 · 2025: 550 · 2024: 456 · 2023: 230 · 2022: 45
FWCI
27.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Pharmaceutica Sinica B (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
medication optimization, tissue selectivity, structure-activity relationship, target validation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review